On March 18, 2022, the FDA approved nivolumab and relatlimab-rmbw (brand name Opdualag) for adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. Brand OPDUALAG (nivolumab and relatlimab-rmbw) injection can be imported for personal use under "patient name basis" treatment in India. For this applicant is required to make an request application with required document. IPN, New Delhi will do the necessary process to obtain permission from Drugs Controller General (India) to import. If you have questions, please email IPN Support Team or Call Indian Pharma Network on +91 9891296838 (Mr. Tarun) / 9811747774 (Mr. Neeraj) for price list or cost in India.
Healthcare Professional In India
If you have any question, please email IPN Support Team or Call Indian Pharma Network for OPDUALAG (nivolumab and relatlimab-rmbw) injection price list or cost in India. on
Mr. Tarun:- +91 9891 296 838
Mr. Neeraj:- +91 9811 747 774
We are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.
Therapeutic indications and Usage FDA approves Opdualag for unresectable or metastatic melanoma On March 18, 2022, the Food and Drug Administration approved nivolumab and relatlimab-rmbw (Opdualag, Bristol-Myers Squibb Company) for adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. Opdualag is a fixed-dose combination of the LAG-3-blocking antibody relatlimab and the programmed death receptor-1 blocking antibody nivolumab.
Source content : www.accessdata.fda.gov
IPN, New Delhi can facilitate patient to import of "OPDUALAG (nivolumab and relatlimab-rmbw) injection" in small quantities for personal use. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.
For procurement cost of OPDUALAG (nivolumab and relatlimab-rmbw) injection in India, Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the OPDUALAG (nivolumab and relatlimab-rmbw) injection medicine cost price in India.
The order for OPDUALAG (nivolumab and relatlimab-rmbw) injection will be confirmed only after
1. submitting Form 12A, along with the prescription of the Registered Medical Practitioner (RMP).
2. Permission from obtained from the office of the Drugs Controller General (India).
3. Availability of OPDUALAG (nivolumab and relatlimab-rmbw) injection from authorised distributor.
Nivolumab and relatlimab-rmbw is approved to treat: Melanoma that is metastatic or cannot be removed by surgery. It is used in adults and children aged 12 years and older. Nivolumab and relatlimab-rmbw is a combination form of nivolumab and relatlimab.
Nivolumab/relatlimab, sold under the brand name Opdualag, is a fixed-dose combination medication use to treat melanoma. It contains nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody. It is given by intravenous infusion. The combination was approved for medical use in the United States in March 2022.
OPDUALAG (nivolumab and relatlimab-rmbw) injection, for intravenous use Initial U.S. Approval: 2022
Injection: 240 mg of nivolumab and 80 mg of relatlimab per 20 mL (12 mg and 4 mg per mL) in a single-dose vial.
For OPDUALAG (nivolumab and relatlimab-rmbw)Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody Combination Opdualag (nivolumab and relatlimab) for Treatment of Patients with Unresectable or Metastatic Melanoma For More Details
Nivolumab Plus Relatlimab Aims to Become Primary Treatment Option for Advanced Melanoma For More Details
Step 1. Send a request for your medicine online:-Applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP).
Step 2. Verification of documents:-We verify your a prescription and necessary documents to import drugs in small quantities for personal use.
Step 3. Permission to Import:-After getting approval of Drugs Controller General (India), we start the process to import of drugs as mentioned in prescription for personal use.
Step 4. We source your medicine:-Our expert sourcing team work with our global network of suppliers to find you the best price. Once we have found you the lowest possible cost for your medicine, we will present you with a final offer for your approval.
Step 5. Delivery of medicine:-After you have accepted our offer, our experienced logistics team will arrange all the shipping and transportation of your medicine.
Doctor’s Prescription –
We would require prescription from Registered Medical Practitioner (RMP) stating product name, dosage, duration of treatment and diagnosis.
Patient’s Medical history –
We would require all test reports and medical reports of the patient for last 3 months.
Patient’s Identity card –
We will require scan copy of patient’s identity card and proof of residence to initiate documentation process.
Almost all countries across the world have provisions for granting access to drugs prior to marketing approval for personal use for patients who have exhausted all other treatment options available in their country. Indian Pharma Network, New Delhi can help patients in accessing/importing Ant-cancer medicines, unapproved in their home country against a legitimate prescription and in conformity with all local laws and regulations of their home country.
Send your query to find out -
OPDUALAG (nivolumab and relatlimab-rmbw) price in South East Asia – China (Beijing, Chongqing, Shanghai, Tianjin and Shenzhen), Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong.
OPDUALAG (nivolumab and relatlimab-rmbw) price in United Arab Emirates – Iraq, Iran, Saudi Arabia, Jordan.
OPDUALAG (nivolumab and relatlimab-rmbw) price in North America – Mexico.
OPDUALAG (nivolumab and relatlimab-rmbw) price in South America – Argentina, Brazil, Chile, Colombia, Peru, Venezuela.
OPDUALAG (nivolumab and relatlimab-rmbw) price in Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia.
OPDUALAG (nivolumab and relatlimab-rmbw) price in Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia.
OPDUALAG (nivolumab and relatlimab-rmbw) price in African Countries – Algeria, Mauritius, Uganda, Zimbabwe.
OPDUALAG (nivolumab and relatlimab-rmbw) price in Australia and New Zealand.
Your order will be shipped to you by our partner couriers, such as DHL, UPS and specialised cold chain couriers. If you would like your order to be shipped by a specific courier, please inform us when you place the order. Our standard delivery time varies from 5 to 10 working days. The shipping cost depends on the medicine and the destination country. After making an enquiry, you will receive a detailed quote that includes the shipping costs.